The study used the company's older GLP-1 agonist therapy Saxenda (liraglutide), which requires a daily injection, rather than its top-selling once-weekly obesity drug Wegovy (semaglutide), and ...

Lexaria Bioscience (LEXX) it has received the necessary independent ethics board approval required for its contract research organization to ...

Wegovy), and over 2,500 participants were prescribed liraglutide (Victoza, Saxenda). The researchers followed the participants through the end of 2023 to determine the effects the weight loss ...

The approval of the once-daily injection (18 mg/3 mL), as an adjunct to diet and exercise, is intended to help with drug shortages and improve patient access. The generic liraglutide includes a ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

liraglutide also underpins Novo’s older weight loss drug Saxenda and its insulin-degludec-based diabetes combination therapy Xultophy. While a newer class of GLP-1s based on Novo’s semaglutide ...

AstraZeneca), liraglutide (Victoza/Saxenda, Novo Nordisk), semaglutide (Wegovy, Novo Nordisk) and tirzepatide (Zepbound, Eli Lilly) for the treatment of diabetes or obesity that reported on ...

The Study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda® ("DehydraTECH-liraglutide") to the conventional injected liraglutide (Saxenda®).